Anti-drug antibodies (ADAs) can hinder the development of complex therapeutic modalities, like bispecific molecules and gene therapies. Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development.
Download this white paper to learn how a robust ADA assay was developed that is capable of detection at the requisite sensitivity to support accurate monitoring of ADA in host-derived samples and enable meaningful interpretation of PK data obtained from the preclinical animal model.